Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICE 1202
- Development stage
- Preclinical
- Lead developer
- iCeutica
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ICE 1202 is a preclinical-stage small molecule drug candidate being developed by iCeutica for the treatment of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and allergic diseases. The drug is designed as an inhaled formulation, likely utilizing iCeutica's proprietary SoluMatrix fine particle technology to optimize delivery and efficacy within the lungs. It is part of a series of respiratory assets (including ICE 1203 and ICE 1204) aimed at improving the therapeutic profile of inhaled medications through enhanced solubility and bioavailability of the active pharmaceutical ingredient.
Beyond the preview
Go deeper on ICE 1202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICE 1202.